- Energizer Holdings Inc (NYSE:ENR) reported a first-quarter FY23 sales decline of 10% year-on-year to $765.10 million, missing the consensus of $785.86 million.
- The gross margin for the quarter contracted 220 basis points to 39%.
- Selling, general and administrative expenses, adjusted, fell 2.2% to $114.1 million.
- The company held $280.3 million in cash and equivalents as of Dec. 31, 2022.
- Adjusted EBITDA of $145.6 million decreased 10% Y/Y.
- Adjusted EPS of $0.72 missed the analyst consensus of $0.76.
- Outlook: Energizer maintained its forecast for FY23 organic revenue to increase low single digits.
- The company sees FY23 Adjusted EPS of $3.00 – $3.30 versus the Street view of $3.13.
- ENR expects Adjusted EBITDA of $585 million – $615 million.
- Price Action: ENR shares are trading lower by 8.62% at $34.04 on the last check Monday.
Medical Cannabis For Autism: Zelira Receives $8.6M For FDA Clinical Trials For Treatment
Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a developer of cannabinoid-based medicines, will conduct FDA Phase 2 and Phase 3 clinical trials for its HOPE-1 treatment of Autism Spectrum Disorder (ASD).
